Epigenetics Market
Number of pages: 100 | Report Format: PDF | Published date: June 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.90 billion |
|
Revenue Forecast in 2031 |
US$ 6.64 billion |
|
CAGR |
14.92% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product Type, Technology, Application, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global epigenetics market was valued at US$ 1.90 billion in 2022 and is expected to register a revenue CAGR of 14.92 % to reach US$ 6.64 billion by 2031.
Epigenetics Market Fundamentals
Epigenetics studies heritable gene expression or cellular phenotype changes that occur without alterations to the underlying DNA sequence. It involves modifications to the DNA structure and the proteins associated with DNA, which can influence gene activity and expression. Epigenetic modifications play a crucial role in regulating gene expression patterns during development, cellular differentiation, and response to environmental cues. The primary mechanisms of epigenetic regulation include DNA methylation, histone modifications, and non-coding RNA molecules. DNA methylation involves adding a methyl group to the DNA molecule, often repressing gene expression.
Epigenetics Market Dynamics
There has been a surge in research activities focused on understanding the role of epigenetic modifications in various diseases and conditions. Researchers are exploring the potential of epigenetic biomarkers for early disease detection, prognosis, and personalized treatment approaches. This growing interest in epigenetic research has fueled the demand for epigenetics tools, technologies, and services. Advances in technologies for studying epigenetic modifications, such as next-generation sequencing, microarray analysis, and mass spectrometry, have revolutionized the field. These technological developments have enabled researchers to analyze epigenetic changes on a genome-wide scale, providing valuable insights into disease mechanisms and epigenetic regulation. The availability of advanced tools and platforms has contributed to the growth of the epigenetics market. Chronic diseases, including cancer, cardiovascular diseases, neurodegenerative disorders, and diabetes, remain major global health challenges. Personalized medicine aims to provide tailored healthcare interventions based on an individual's unique genetic and epigenetic profile. The pharmaceutical and biotechnology industries have recognized the potential of epigenetics in drug discovery and development. The industry's interest in epigenetics has resulted in collaborations, partnerships, and investments in epigenetics research and development, further driving market growth. For instance, Chroma Medicine, Inc. (Chroma), a new genomic medicine firm pioneering epigenetic editing, was founded in November 2021 with USD 125 million in investment to address a wide spectrum of disorders and become the technology of choice for gene regulation.
Epigenetic research and analysis involve complex methodologies and technologies. Technical challenges include the need for high-quality samples, standardization of experimental protocols, and optimization of data analysis pipelines. Variability in testing procedures and data interpretation can lead to inconsistencies and hinder the comparability of results across studies. Despite significant progress, our understanding of epigenetic mechanisms and their functional consequences is still evolving. The complexity of epigenetic regulation, the interplay between different epigenetic modifications, and the dynamic nature of the epigenome present challenges in deciphering cause-effect relationships and identifying functional implications of specific epigenetic changes. Analyzing and interpreting epigenomic data on a large scale can be complex. High-throughput technologies generate vast amounts of data, and extracting meaningful insights from these datasets requires sophisticated bioinformatics tools and computational approaches. Integrating epigenetic data with other omics data, such as genomics and transcriptomics, poses additional challenges due to differences in data formats and integration methodologies. However, there have been concerns about the reproducibility of epigenetic studies, including variations in experimental protocols, data analysis pipelines, and limited sample sizes. Robust validation of epigenetic biomarkers and reproducibility of research findings across different laboratories and cohorts are critical for establishing epigenetic assays' clinical utility and reliability. Public perception and acceptance of epigenetic interventions and diagnostics may also influence the adoption and commercialization of epigenetic products. Addressing ethical concerns and ensuring transparency in research and clinical applications are important for building public trust and fostering responsible use of epigenetic technologies.
Epigenetics Market Ecosystem
The global epigenetics market has been analyzed from the following perspectives: by product type, technology, application, and region.
Epigenetics Market by Product Type
Based on the product type, the global epigenetics market is segmented into instruments, reagents, kits, enzymes, and services.
The reagents segment dominated the global market with the largest revenue share of around 32.4% in 2022. Reagents are fundamental components in experimental workflows for studying epigenetic modifications. They are required for processes such as DNA and RNA extraction, bisulfite conversion for DNA methylation analysis, chromatin immunoprecipitation (ChIP) assays, and various enzymatic reactions. These reagents are indispensable for performing laboratory-based experiments, making them a critical component of epigenetic research. Reagents are consumable products that need to be regularly replenished as they are used up in experiments. Researchers and laboratories continually require reagents for their ongoing studies, resulting in frequent consumption and repeat purchases. This consistent demand contributes to the revenue generated by the reagents segment. The field of epigenetics encompasses various techniques and methodologies, each requiring specific reagents tailored to its specific requirements. The ongoing research and development activities in the field drive the demand for new and improved reagents, contributing to the revenue generated by this segment. Reagents often have higher profit margins than other epigenetics market segments, such as instruments or software. This is because the production and distribution of reagents involve relatively lower costs compared to the development and manufacturing of complex instruments or software platforms. Consequently, the higher pricing structure of reagents can contribute to their larger revenue share in the overall market.
Epigenetics Market by Technology
Based on the technology, the global epigenetics market is segmented into histone acetylation, DNA methylation, chromatin structures, histone methylation, large non-coding RNA, and microRNA modification.
DNA methylation accounted for a prominent revenue share of nearly 67.9% in 2022. DNA methylation is one of the most well-known and extensively studied epigenetic modifications. It involves adding a methyl group to the DNA molecule, predominantly occurring at CpG sites. DNA methylation is crucial in gene regulation, genomic stability, and cellular processes. The established understanding and extensive research on DNA methylation have resulted in the development of various technologies and tools specifically targeting this epigenetic modification. DNA methylation has been implicated in developing and progressing numerous diseases, including cancer, neurological disorders, cardiovascular diseases, and autoimmune disorders. The potential of DNA methylation as a biomarker for disease diagnosis, prognosis, and therapeutic response prediction has fueled the demand for DNA methylation analysis tools and services. DNA methylation patterns can serve as valuable biomarkers for various diseases, particularly cancer. DNA methylation analysis techniques have been well-established over the years, with multiple methodologies available for studying DNA methylation patterns. These include bisulfite conversion-based methods, such as bisulfite sequencing and methylation-specific PCR (MSP), and array-based technologies, like methylation microarrays. The availability of established technologies and platforms targeting DNA methylation analysis simplifies the workflow and promotes the adoption of these methods in both research and clinical settings. The DNA methylation field has attracted significant research and development investments. DNA methylation-based tests and assays have gained regulatory approvals for clinical use in some applications.
Epigenetics Market by Application
Based on the application, the global epigenetics market is segmented into oncology and non-oncology.
Oncology dominated the global market with around 70.02% of the revenue share in 2022. Cancer is a widespread and significant global health concern. The high prevalence of various types of cancers drives the demand for effective diagnostic and treatment approaches. For instance, according to the American Cancer Society journal, it was noted that in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths occurred in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Epigenetic modifications play a crucial role in cancer development and progression, making the oncology field a major area of focus for epigenetics research. As a result, the oncology segment benefits from the substantial market size associated with cancer-related applications. Epigenetic alterations are closely associated with cancer initiation, progression, and response to therapy. Epigenetic biomarkers can be used for cancer diagnosis, prognosis, and monitoring of treatment response. By analyzing specific epigenetic modifications, such as DNA methylation patterns or histone modifications, researchers and clinicians can identify molecular signatures that provide insights into cancer subtypes, predict patient outcomes, and guide treatment decisions. The diagnostic and prognostic potential of epigenetics in oncology drives the demand for related products and services, contributing to the revenue generated by the oncology segment. Epigenetic drugs, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been developed and approved for certain types of cancer. These drugs can modulate gene expression patterns by altering the epigenetic landscape, potentially leading to tumor suppression or sensitizing cancer cells to other treatments. Researchers and pharmaceutical companies are actively investigating the role of epigenetic modifications in different types of cancers, identifying new biomarkers, and developing novel epigenetic therapies. The strong focus on oncology-related epigenetic research drives the demand for related products, such as reagents, instruments, and services, resulting in a larger revenue share of the oncology segment. The clinical translation of epigenetics in oncology has progressed rapidly. Several epigenetic biomarkers and therapeutic interventions have entered clinical practice and gained regulatory approvals.
Epigenetics Market by Region
Based on the region, the global epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominated the global market with a revenue share of 39.54% in 2022. North America has a well-developed and advanced healthcare infrastructure. The region has a strong network of hospitals, research institutions, and academic centers actively engaging in epigenetic research and applications. The availability of state-of-the-art facilities, cutting-edge technologies, and skilled healthcare professionals enables the efficient adoption and implementation of epigenetics in clinical practice and research, driving market growth. North America has a robust research and development ecosystem, with significant investments and collaborations in epigenetics. The strong research focus attracts funding, talent, and resources, promoting the growth of the epigenetics market in North America. North America has a high prevalence of chronic diseases, including cancer, cardiovascular diseases, neurological disorders, and metabolic disorders. For instance, according to a CDC report, it was estimated that in the United States in 2019, 1,752,735 new cancer cases were reported, and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported, and 146 people died of cancer. The large patient population, coupled with a focus on precision medicine, contributes to the substantial market size in North America. North America is home to numerous major pharmaceutical and biotechnology companies investing in epigenetics. These companies engage in the development and commercialization of epigenetic-based drugs, diagnostic tests, and research tools. Their strong market presence, research capabilities, and financial resources drive the growth of the epigenetics market in the region. Governments in North America provide support and funding for scientific research and development, including epigenetics. Government agencies, such as the National Institutes of Health (NIH) and the National Cancer Institute (NCI), allocate substantial funds for epigenetic research. The availability of government support and funding initiatives encourages innovation, collaboration, and market growth in the epigenetics sector.
Epigenetics Market Competitive Landscape
The prominent players operating in the global epigenetics market are:
Epigenetics Market Strategic Developments
Epigenetics studies heritable changes in gene expression or cellular phenotype that occur without alterations to the underlying DNA sequence.
Illumina Inc., ValiRx Plc., Abcam Plc., and Hologic Inc. are some of the key companies operating in the global epigenetics market.
Limited knowledge of epigenetic mechanisms and problems related to data interpretation and integration are some of the restraints obstructing the growth of the global market.
The oncology segment dominated the global epigenetics market in 2022.
The high potential of epigenetics in drug discovery and development and the increasing prevalence of cancer are some of the major factors driving the global market.
*Insights on financial performance are subject to the availability of information in the public domain